Hengrui Pharma

Hengrui Pharma was established in 1970 as a national pharmaceutical company dedicated to the development and promotion of innovative and high-quality medicines. It has grown into a well-known supplier of anti-cancer drugs, surgical medications, and imaging interventional products in China. In the 2021 TOP50 global pharmaceutical enterprises ranking published by the US magazine "Pharmaceutical Executive," Hengrui Pharma made the list for the third consecutive year, with its ranking rising to 38th place. The company has been consistently recognized as one of the top 100 pharmaceutical enterprises in China’s pharmaceutical industry and ranked first as the best industrial enterprise in China's pharmaceutical R&D product line in 2021. Over the past five decades, Hengrui Pharma has remained rooted in China while looking towards the world, focusing on health care, targeting cutting-edge fields, and overcoming challenges to promote high-quality development in the pharmaceutical industry. The company prioritizes technological innovation as its primary development strategy. In recent years, it has maintained substantial investment in R&D, with a cumulative R&D investment of 6.203 billion yuan in 2021, accounting for 23.95% of its operating revenue, placing it at the forefront of the industry. The company has established research and development centers or branches in the United States, Europe, Japan, Australia, and various locations in China, building a large-scale, professional, and highly capable global R&D team of more than 5,400 people. Currently, the company has received approval for 11 innovative drugs, with over 60 more in clinical development. Its R&D pipeline is extensive, covering not only its traditional stronghold in oncology but also making forward-looking investments in multiple therapeutic areas such as autoimmune diseases, pain management, cardiovascular diseases, and metabolic disorders. Additionally, the company has developed a series of proprietary, world-class new technology platforms that provide a strong foundation for innovative R&D. As of the end of 2021, the company had filed 1,806 patent applications, including 494 PCT patents, and owned 360 valid authorized invention patents domestically and 478 authorized patents in regions like Europe, the US, and Japan.